US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract, Snapshot, Market Analysis & Market Definition: Global Attention Deficit Hyperactivity Disorder (ADHD) Market The global attention deficit hyperactivity disorder market size was valued at USD 16.4 billion in 2018 and is estimated to exhibit a CAGR of 6.4% over the forecast period. Product launches across the globe, approval of new drugs, and increased research and development activities are likely to drive the market. Increase in awareness about mental health among the general population and governments is expected to propel the ADHD market. Rising number of people suffering from a host of mental health disorders, including attention-deficit/hyperactivity disorder, has caught the attention of governments around the world, forcing them to take necessary steps to address this condition. In 2016, the U.S. Department of Health & Human Services awarded up to USD 54 million to the Substance Abuse and Mental Health Services Administration (SAMHSA) for the next four years to address the needs of individuals with serious mental illnesses. Similarly, NHS England set up a five-year plan for mental health in 2016. The government committed to implementing this plan by 2020–2021, investing USD 1.27 billion into the project. Therefore, government support, along with growing awareness among various parties, is anticipated to boost the market. Approval and commercialization of new drugs by market players is also expected to play a crucial role in driving market growth over the coming years. For instance, in August 2017, Shire launched FDA-approved MYDAYIS for the treatment of ADHD patients of the age 13 and older. Market Segmentation, Outlook & Viewpoint: Global Attention Deficit Hyperactivity Disorder (ADHD) Market Drug Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025) Amphetamine Methylphenidate Lisdexamfetamine Dexmethylphenidate Atomoxetine Guanfacine Clonidine Bupropion Drug Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025) Stimulant Non-stimulant Demographic Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025) Adult (Aged 18 and above) Children Distribution Channel Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025) Retail Pharmacy Hospital Pharmacy Key Players, Recent Developments & Regional Insights: Global Attention Deficit Hyperactivity Disorder (ADHD) Market By type of drug, the market has been segmented into stimulant and non-stimulant drugs. Stimulant drugs include Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate. Non-stimulant drugs include Atomoxetine, Guanfacine, Clonidine, and Bupropion. The stimulant segment accounted for the largest share in the ADHD market in 2018 and is expected to maintain its dominance throughout the forecast period. This can be attributed to high demand for these drugs due to their effectiveness in treating symptoms of attention-deficit/hyperactivity disorder, ongoing clinical trials, and government support for the use of stimulants in the treatment of mental health disorders. In April 2016, Tris Pharma, Inc. announced the launch of its FDA-approved liquid ADHD medication Dyanavel XR (amphetamine), which is used to treat patients over the age of six. Non-stimulants are expected to exhibit the fastest growth rate during the forecast period due to their long-lasting effect compared to stimulants. The fact that these drugs present no risk of substance abuse is also a key factor boosting segment growth. Furthermore, an increasing number of market players have been investing in the development of non-stimulant drugs for attention-deficit/hyperactivity disorder, which is driving the segment. Demographic Insights On the basis of demographics, the attention-deficit/hyperactivity disorder (ADHD) market has been bifurcated into children (2-17 years of age) and adults (aged 18 and above). The adult segment held the largest share in the market in 2018 and this can be attributed to a large patient population. According to ADD Health and Wellness Centers, Inc., attention-deficit/hyperactivity disorder affects more than 4.0% of the adult population in U.S. According to the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA), in 2015, there were 17.2 million individuals who used stimulants, of which 1.8 million were youth (age 12-17) and 4.9 million were adults (age 18-25). Distribution Channel Insights Based on distribution channel of ADHD drugs, the market has been segmented into hospital and retail pharmacies. In 2018, retail pharmacy accounted for the maximum market share. Increasing number of prescriptions and rise in patient care initiatives by retail pharmacies have driven the segment. ADHD inpatients are fewer in number compared to patients in homecare settings owing to the lengthy nature of the treatment of the condition. Patients prefer purchasing drugs from retail pharmacies rather than hospitals and therefore, the segment is expected to retain its lead throughout the forecast period. The segment is also anticipated to register the highest CAGR of 6.6% from 2019 to 2025. Regional Insights North America dominated the global market and accounted for more than 68.0% of the total market in 2018. This can be attributed to the large volume of drug prescriptions every year, increasing product launches, and rise in collaboration among players to enhance market penetration and for product development. In August 2017, Shire launched a new prescription drug MYDAYIS (latest formulation of Adderall) in U.S. for ADHD patients over the age of 13. In October 2018, Dr. Reddy’s Laboratories launched Atomoxetine capsule to treat attention-deficit/hyperactivity disorder in U.S. Hence, commercialization of products is expected to boost the North America market. Europe is expected to grow at the fastest rate during the forecast period due to increasing awareness about mental health, rising prevalence of attention-deficit/hyperactivity disorder, high consumption of additives and preservatives, and improving coverage for treatment of the condition. ADHD Market Share Insights Key players in the market include Eli Lily & Company; Pfizer; Johnson & Johnson Services, LLC; Lupin; Shire; Mallinckrodt; Prude Pharma L.P.; and NEOS Therapeutics Inc. Development of effective and economical products and geographical expansion are some of the major strategies adopted by market players to remain competitive. For instance, in December 2015, Pfizer received the U.S. FDA approval of Quillichew ER, a chewable tablet for treatment of ADHD in patients 6 years and above. This is available in 20mg, 30mg, and 40mg formulations. Furthermore, in February 2018 Lupin launched a generic version of Kapvay in U.S, which expanded its product line for the treatment of attention-deficit/hyperactivity disorder. Key Insights Covered: Global Attention Deficit Hyperactivity Disorder (ADHD) Market 1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Attention Deficit Hyperactivity Disorder (ADHD) industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Attention Deficit Hyperactivity Disorder (ADHD) industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Attention Deficit Hyperactivity Disorder (ADHD) industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Attention Deficit Hyperactivity Disorder (ADHD) industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Attention Deficit Hyperactivity Disorder (ADHD) industry. Research Methodology: Global Attention Deficit Hyperactivity Disorder (ADHD) Market
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other
Table of Content Chapter 1 Executive Summary 1.1 Market SnapshotChapter 2 Market Definitions 2.1 ObjectiveChapter 3 Research Methodology 3.1 Information Procurement 3.2 Data AnalysisChapter 4 Market Variables, Trends, & Scope 4.1 Market Segmentation and Scope 4.1.1 Market driver analysis 184.108.40.206 Increasing prevalence of ADHD 220.127.116.11 Increasing awareness regarding ADHD among physicians and patients 4.1.2 Market restraint analysis 18.104.22.168 Less availability of non-stimulants ADHD drugs 22.214.171.124 Underdiagnosis of ADHD 4.2 Penetration & | read more...